Anticoagulation strategies in atrial fibrillation

Reviews in Cardiovascular Medicine

Volumn 13, Issue 1, 2012, Pages

  Menezes, Arthur R ^a   Artham, Surya ^a   Lavie, Carl J ^a,b   Khatib, Sammy ^a  

^a JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTIVITAMIN K; APIXABAN; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOEMBOLIC STROKE; CARDIOVERSION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEATH; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS (TOPIC); PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MIDDLE AGED; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84863093371     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0616     Document Type: Review

References (83)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Bogousslavsky J, Van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990;40,1046-1050. (Pubitemid 20213969)
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N. (Pubitemid 28507114)
4. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74,236-241. (Pubitemid 24239044)
5. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469-473.
6. Friberg J, Scharling H, Gadsbøll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol. 2003;92:1419-1423. (Pubitemid 37532563)
7. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375. (Pubitemid 32424106)
8. Ruo B, Capra AM, Jensvold NG, Go AS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol. 2004;43:429-435. (Pubitemid 38167704)
9. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925-1932.
10. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-2477. (Pubitemid 39552671)
11. Camm AJ, Obel OA. Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiol. 1996;78:3-11.
12. Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22:1359-1366. (Pubitemid 23316359)
13. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol. 1989;13:617-623. (Pubitemid 19073928)
14. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994;23:961-969. (Pubitemid 24090884)
15. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):546S-592S. (Pubitemid 351892972)
16. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-1026. (Pubitemid 37087616)
17. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870. (Pubitemid 32537350)
18. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123:484-488.
19. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
20. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360-1420.
21. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
22. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501. (Pubitemid 29482392)
23. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-179. (Pubitemid 19038801)
24. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84:527-539.
25. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-1262.
26. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J. 1999;138:137-143. (Pubitemid 29331134)
27. Benavente O, Hart RG. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci. 1997;153:110; author reply 112.
28. Benavente O, Hart R, Koudstaal P, et al. Antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2000;(2):CD001925.
29. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-1511.
30. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-1412.
31. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349-355.
32. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448. (Pubitemid 35340540)
33. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867. (Pubitemid 351650486)
34. Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39-43. (Pubitemid 30034856)
35. Yusuf S, Zhao F, Mehta SR, et al Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
36. Connolly SJ, Pogue J, Hart RG, et al ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.
37. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators. N Engl J Med. 1993;329:673-682.
38. Berger PB, Bhatt DL, Fuster V, et al CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121:2575-2583.
39. Bhatt DL, Fox KA, Hacke W, et al CHARISMA Investigators. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2005;150:401.
40. Bhatt DL, Fox KA, Hacke W, et al CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354:1706-1717.
41. Wang TH, Bhatt DL, Fox KA, et al CHARISMA Investigators. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007;28:2200-2207. (Pubitemid 47428941)
42. Connolly S, Pogue J, Hart R, et al ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.
43. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105:453-463. (Pubitemid 40070721)
44. Akins PT, Feldman HA, Zoble RG, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. 2007;38:874-880. (Pubitemid 46568446)
45. Teitelbaum JS, von Kummer R, Gjesdal K, et al SPORTIF Executive Steering Committee. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. Can J Neurol Sci. 2008;35:160-165. (Pubitemid 351831051)
46. Ford GA, Choy AM, Deedwania P, et al; SPORTIF III, V Investigators. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. Stroke. 2007;38:2965-2971. (Pubitemid 350035691)
47. Connolly SJ, Ezekowitz MD, Yusuf S, et al RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
48. Ezekowitz MD, Wallentin L, Connolly SJ, et al RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246-2253.
49. Nagarakanti R, Ezekowitz MD, Oldgren J. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131-136.
50. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11.
51. Wartak SA, Bartholomew JR. Dabigatran: will it change clinical practice? Cleve Clin J Med. 2011;78:657-664.
52. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144-1150.
53. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation. 1995;92:962-967.
54. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med. 1989;87(3B):2S-9S. (Pubitemid 19249543)
55. Olson ST, Richard B, Izaguirre G, et al. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie. 2010;92:1587-1596.
56. Perzborn E, Roehrig S, Straub A, et al. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10:61-75.
57. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3:1843-1853. (Pubitemid 41716571)
58. Prandoni P, Tormene D, Perlati M, et al. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs. 2008;17:773-777. (Pubitemid 351843619)
59. Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost. 2009;102:811-815.
60. Bousser MG, Bouthier J, Büller HR, et al Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008 26;371:315-321.
61. Weitz JI, Hirsh J. New anticoagulant drugs. Chest. 2001;119(1 suppl): 95S-107S. (Pubitemid 32154196)
62. De Caterina R. The current role of anticoagulants in cardiovascular medicine. J Cardiovasc Med (Hagerstown). 2009;10:595-604.
63. Yusuf S, Mehta SR, Chrolavicius S, et al Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
64. Samama MM. The mechanism of action of rivaroxaban-an oral, direct Factor Xa inhibitor-compared with other anticoagulants. Thromb Res. 2011;127:497-504.
65. Mousa SA. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Methods Mol Biol. 2010;663:181-201.
66. ROCKET AF Study Investigators. Rivaroxaban-once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-347.e1.
67. Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment. Am Heart J. 2010;159:348-353.
68. AVERROES study of investigational agent apixaban closes early due to clear evidence of efficacy [press release]. New York, NY, and Princeton, NJ: Pfizer/Bristol-Myers Squibb; June 10, 2010.
69. Lopes RD, Alexander JH, Al-Khatib SM, et al ARISTOTLE Investigators. Apixaban for Reduction in Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-339.
70. Granger CB, Alexander JH, McMurray JJ, et al ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
71. Gokterin O, Uzener N, Ata N, et al. Does short-term anticoagulation with heparin increase risk for microemboli patients undergoing transesophageal guided electrical cardioversion for atrial fibrillation? A transcranial Doppler ultrasonography study. Int J Cardiol. 2003;88:107-112. (Pubitemid 36351421)
72. Nabavi DG, Allroggen A, Reinecke H, et al. Absence of circulating microemboli in patients with atrial fibrillation undergoing electric cardioversion. Cerebrovasc Dis. 2001;11:95-99. (Pubitemid 32171167)
73. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82:1545-1547, A8.
74. Olshansky B. High intensity anticoagulation for cardioversion of atrial arrhythmias? The shocking truth. J Am Coll Cardiol. 2002;40:934-936. (Pubitemid 34994987)
75. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-216.
76. Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40:926-933. (Pubitemid 34994986)
77. Manning WJ, Silverman DI, Keighly CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5 year study. J Am Coll Cardiol. 1995;25,1354-1361.
78. Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Arch Intern Med. 1995;123:817-822.
79. Fatkin D, Scalia G, Jacobs N, et al. Accuracy of biplane transesophageal echocardiography in detecting left atrial thrombus. Am J Cardiol. 1996;77,321-323.
80. Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation. 1994;89:2509-2513.
81. Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995;129,71-75.
82. Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126,615-620. (Pubitemid 27172188)
83. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):429S-456S. (Pubitemid 39302603)